On January 10, 2020, the Securities and Exchange Commission ("SEC") announced that Agilent Technologies, Inc. ("Agilent"), a biopharmaceutical company based in New York City, has agreed to pay $1.5 billion to acquire a large number of microcap companies.  The SEC's complaint, filed in federal court in Manhattan, alleges that Agilent violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The SEC's complaint charges that Agilent violated Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and that Agilent violated Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Agilent has agreed to pay $1.5 billion in disgorgement, prejudgment interest, and a civil penalty.  The settlement is subject to court approval.  The SEC's investigation, which is continuing, has been conducted by Dylan Vatnsdal, Robert McMahon, and Amy Gwiazda of the SEC's Market Abuse Unit.  The litigation is continuing.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of New York and the Federal Bureau of Investigation.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.